is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases.
ChemoCentryx has been acquired by Amgen (NASDAQ: AMGN) for $4 billion in cash in October 2022.
San Carlos, CA
https://www.chemocentryx.com